Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes. Therefore, improving GLP-1 receptor agonist (GLP-1RA) stability is a major obstacle for drug development. We analyzed human GLP-1, DPP-4, and GLP-1 receptor structures and designed three GLP-1RAs, which were introduced into fusion protein fragments and changed in the overall conformation. This modification effectively prevented GLP-1RAs from entering the DPP-4 active center without affecting GLP-1RAs’ ability to bind to GLP-1R, the new GLP-1RA hypoglycemic effect lasting for >24 h. Through molecular modeling, molecular dynamics calculation, and simulation, possible tertiary structure models of GLP-1RAs were obtained; molecular docking with DPP-4 and GLP-1R showed access to the fusion protein. The overall conformational change of GLP-1RAs prevented DPP-4 binding, without affecting GLP-1RAs’ affinity to GLP-1R. This study provides important drug design ideas for GLP-1RA development and a new example for application of structural biology-based protein design in drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs result from intricate structural modifications to GLP-1, enabling them to not only replicate the pharmacological functions of GLP-1 but also impede its hydrolysis by DPP-4, thereby extending the drug’s half-life.47,48”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A smooth particle mesh Ewald method
Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995) · The Journal of Chemical Physics · doi:10.1063/1.470117 · Cited by 22,514 · cited 1×
“4 nm, the adjacency list was updated every 20 fs, and the PME algorithm was used to calculate of long-range electrostatic interaction [44], where the interpolation order was set to 4 and the tolerance was set to 10−5.”
MethodSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 2×
“Incidence of diabetes has shown an increasing trend, the 9th edition of the Global Diabetes Atlas(Saeedi et al. 2019) which was released by the International Diabetes Federation (IDF) in 2019, shows that as of 2019, approximately 463 million people aged between 20-79 have diabetes (the vast majority are type II diabet…”
BackgroundInfluentialComparison of multiple Amber force fields and development of improved protein backbone parameters
Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21123 · Cited by 6,914 · cited 1×
“The protein force field used was the AMBER99SB [41] force field.”
MethodI-TASSER: a unified platform for automated protein structure and function prediction
Roy, A., Kucukural, A., & Zhang, Y. (2010) · Nature Protocols · doi:10.1038/nprot.2010.5 · Cited by 6,170
Verification of protein structures: Patterns of nonbonded atomic interactions
Colovos, C., & Yeates, T. O. (1993) · Protein Science · doi:10.1002/pro.5560020916 · Cited by 4,498 · cited 3×
“VERIFY 3D showed that 80.25% of residues had a 3D-1D score ≥ 0.2, and ERRAT scored model3 as 91.78.”
MethodInfluentialP-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation
Hess, B. (2008) · Journal of Chemical Theory and Computation · doi:10.1021/ct700200b · Cited by 3,987
Assessment of protein models with three-dimensional profiles
Lüthy, R., Bowie, J. U., & Eisenberg, D. (1992) · Nature · doi:10.1038/356083a0 · Cited by 3,525 · cited 1×
“VERIFY 3D [38,39] and ERRAT [40] were used to evaluate the predicted models and eliminate unqualified models.”
MethodA Method to Identify Protein Sequences That Fold into a Known Three-Dimensional Structure
Bowie, J. U., Lüthy, R., & Eisenberg, D. (1991) · Science · doi:10.1126/science.1853201 · Cited by 2,851 · cited 1×
“VERIFY 3D [38,39] and ERRAT [40] were used to evaluate the predicted models and eliminate unqualified models.”
MethodThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 11×
“, and Drucker, D.J. (2014). Pharmacology, physiology, and mechanisms of action of 578 dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35, 992–1019 [DOI: 10.1210/er.2014-1035]. 579 Pierce, B.G., Wiehe, K., Hwang, H., Kim, B.H., Vreven, T., and Weng, Z. (2014). ZDOCK server: 580 interactive docking prediction of protein…”
BackgroundMethodInfluentialDevelopment of an improved four-site water model for biomolecular simulations: TIP4P-Ew
Horn, H. W., Swope, W. C., Pitera, J. W., Madura, J. D., Dick, T. J., Hura, G. L., & Head-Gordon, T. (2004) · The Journal of Chemical Physics · doi:10.1063/1.1683075 · Cited by 2,121 · cited 1×
“Following this, 12,413 TIP4Pew [42] water molecules, 35 sodium ions, and 35 chloride ions were added to the box, which ensured that the total charge of the system was 0 while the salt concentration of the system reached 140 mM.”
MethodZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers
Pierce, B. G., Wiehe, K., Hwang, H., Kim, B.-H., Vreven, T., & Weng, Z. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu097 · Cited by 1,760
Algorithms for macromolecular dynamics and constraint dynamics
van Gunsteren, W. F., & Berendsen, H. J. C. (1977) · Molecular Physics · doi:10.1080/00268977700102571 · Cited by 1,732
Friguet, B., Chaffotte, A. F., Djavadi-Ohaniance, L., & Goldberg, M. E. (1985) · Journal of Immunological Methods · doi:10.1016/0022-1759(85)90044-4 · Cited by 1,234 · cited 1×
“After the reaction, the dissociation constant (Kd) between the target protein and GLP-1 receptor was calculated by plotting(Friguet et al. 1985; Bobrovnik 2003; Martineau 2010) (Kd is equal to the ligand concentration when half of the receptors are bound by ligands.”
MethodDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“However, the high price of chemical modification also hinders the widespread use of such drugs(Elbrond et al. 2002; Madsen et al. 2007; Lau et al. 2015).”
BackgroundEffect of diet on type 2 diabetes mellitus: a review
Khazrai, Y. M., Defeudis, G., & Pozzilli, P. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2515 · Cited by 626
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609 · cited 1×
“The process from the production of GLP-1 to the final inactivation is extremely rapid, occurring within only 1.5-2 minutes(Davidson 2009; Mulvihill and Drucker 2014).”
BackgroundInfluentialExendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464 · cited 1×
“It triggers an immune response and has many side effects(Malhotra et al. 1992; Edwards et al. 2001; Linnebjerg et al. 2007).”
BackgroundCirculation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299 · cited 1×
“GLP-1 is the substrate of the proteolytic enzyme DPP-4, which cleaves and inactivates GLP-1 from the 8th amino acid (alanine) and is metabolized by the kidneys in urine [8].”
BackgroundUnderwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295 · cited 1×
“For the docking of GLP-1R and G1, according to the interaction analysis of the crystal structure of GLP-1R and GLP-1 [48], Leu32, Trp39, Asp67, Arg121, Leu123, Glu127, and Glu128 were selected as the active residues of the GLP-1 receptor, and Gln17, Ala18, Ala19, Lys20, Glu21, Phe22, Ile23, Trp25, and Leu26 were selec…”
MethodStructure-activity studies of glucagon-like peptide-1.
Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., & Kirk, O. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37366-0 · Cited by 282 · cited 1×
“Interestingly, it was found that these mutations could severely weaken the binding ability of GLP-1 and its receptor, thus affecting the function of GLP-1(Adelhorst et al. 1994; Gallwitz et al. 2000; Green et al. 2004; Li et al. 2010).”
BackgroundElbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
De Marinis, Y. Z., Salehi, A., Ward, C. E., Zhang, Q., Abdulkader, F., Bengtsson, M., Braha, O., Braun, M., Ramracheya, R., Amisten, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.007 · Cited by 257 · cited 1×
“Some studies(De Marinis et al. 2010; Ramracheya et al. 2018) have shown that GLP-1 expressed in pancreatic islet α cells can activate protein kinase A (PKA) and inactivate PKA-dependent N-type Ca2+ channels on the surface of α cells due to phosphorylation.”
BackgroundMadsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244 · cited 1×
“However, the high price of chemical modification also hinders the widespread use of such drugs(Elbrond et al. 2002; Madsen et al. 2007; Lau et al. 2015).”
BackgroundThoma, R., Löffler, B., Stihle, M., Huber, W., Ruf, A., & Hennig, M. (2003) · Structure · doi:10.1016/s0969-2126(03)00160-6 · Cited by 238 · cited 1×
“According to the experimental data [47],”
Effect of diet on type 2 diabetes mellitus: A review.
(2017) · Europe PMC (PubMed Central) · Cited by 226
Raab, D., Graf, M., Notka, F., Schödl, T., & Wagner, R. (2010) · Systems and Synthetic Biology · doi:10.1007/s11693-010-9062-3 · Cited by 212 · cited 2×
“The designed amino acid sequence of each GLP-1RA was analyzed using GeneOptimizer [36] or gene expression analysis, and multi-parameter gene optimization.”
MethodEffect of renal impairment on the pharmacokinetics of exenatide
Linnebjerg, H., Kothare, P. A., Park, S., Mace, K., Reddy, S., Mitchell, M., & Lins, R. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02890.x · Cited by 198 · cited 1×
“It triggers an immune response and has many side effects(Malhotra et al. 1992; Edwards et al. 2001; Linnebjerg et al. 2007).”
BackgroundRamracheya, R., Chapman, C., Chibalina, M., Dou, H., Miranda, C., González, A., Moritoh, Y., Shigeto, M., Zhang, Q., Braun, M., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13852 · Cited by 128 · cited 1×
“Some studies(De Marinis et al. 2010; Ramracheya et al. 2018) have shown that GLP-1 expressed in pancreatic islet α cells can activate protein kinase A (PKA) and inactivate PKA-dependent N-type Ca2+ channels on the surface of α cells due to phosphorylation.”
BackgroundAcuna-Goycolea, C., & van den Pol, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1607-04.2004 · Cited by 126 · cited 1×
“In addition, it also has the effect of reducing weight and improving insulin resistance [28,29].”
BackgroundGlucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes
Ahrén, B. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199808)20:8<642::aid-bies7>3.0.co;2-k · Cited by 125 · cited 2×
“GLP-1 is derived from L cells of the intestinal mucosa and is a carboxy-terminated peptide chain sequence obtained by the cleavage of proglucagon by hormone proconvertase 1 (PC1) [3].”
BackgroundGLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 113 · cited 2×
“GLP-1 is a peptide secreted by the pancreas that plays an important role in the glucose metabolic pathway, promoting insulin release in a glucose-dependent manner [27].”
BackgroundBurcelin, R., Dolci, W., & Thorens, B. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90043-4 · Cited by 107 · cited 2×
“Previous studies have shown that GLP-1 modification gradually develops from amino acid mutations and partial amino acid modifications(Burcelin, Dolci, and Thorens 1999; Gallwitz et al. 2000) to the overall structural modification.”
BackgroundResultDetermination of antibody affinity by ELISA. Theory
Bobrovnik, S. A. (2003) · Journal of Biochemical and Biophysical Methods · doi:10.1016/s0165-022x(03)00145-3 · Cited by 85 · cited 2×
“After the reaction, the dissociation constant (Kd) between the target protein and GLP-1 receptor was calculated by plotting(Friguet et al. 1985; Bobrovnik 2003; Martineau 2010) (Kd is equal to the ligand concentration when half of the receptors are bound by ligands.”
BackgroundMethodAdvances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75
Neural integration of satiation and food reward: Role of GLP-1 and orexin pathways
Williams, D. L. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.03.013 · Cited by 74 · cited 2×
“In addition, it also has the effect of reducing weight and improving insulin resistance [28,29].”
BackgroundGLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
Gallwitz, B., Ropeter, T., Morys‐Wortmann, C., Mentlein, R., Siegel, E. G., & Schmidt, W. E. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00095-6 · Cited by 68 · cited 3×
“Interestingly, it was found that these mutations could severely weaken the binding ability of GLP-1 and its receptor, thus affecting the function of GLP-1(Adelhorst et al. 1994; Gallwitz et al. 2000; Green et al. 2004; Li et al. 2010).”
BackgroundResultPeptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Frémaux, J., Venin, C., Mauran, L., Zimmer, R., Guichard, G., & Goudreau, S. R. (2019) · Nature Communications · doi:10.1038/s41467-019-08793-y · Cited by 60 · cited 2×
“In another report, individual residues in the α-helix of wild-type GLP-1 were replaced with three consecutive ureido residues, and the AUC of the blood curve was reduced by approximately 60% compared with that of the vehicle [35].”
MethodGreen, B., Mooney, M., Gault, V., Irwin, N., Bailey, C., Harriott, P., Greer, B., O'Harte, F., & Flatt, P. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800379 · Cited by 57 · cited 1×
“Interestingly, it was found that these mutations could severely weaken the binding ability of GLP-1 and its receptor, thus affecting the function of GLP-1(Adelhorst et al. 1994; Gallwitz et al. 2000; Green et al. 2004; Li et al. 2010).”
BackgroundMalhotra, R. K., Singh, L., Eng, J., & Raufman, J. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90044-u · Cited by 56 · cited 1×
“It triggers an immune response and has many side effects(Malhotra et al. 1992; Edwards et al. 2001; Linnebjerg et al. 2007).”
BackgroundDulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 48 · cited 2×
“For example, some studies have fused GLP-1 molecules with Human serum albumin (Gao et al. 2009), or PEG-modified GLP-1, to increase its molecular volume(Li et al. 2020), while others have increased the half-life of GLP-1RAs by dimerization and antibody fusion(Scheen 2017).”
BackgroundGao, Z., Bai, G., Chen, J., Zhang, Q., Pan, P., Bai, F., & Peng, G. E. N. G. (2009) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.80742 · Cited by 42 · cited 1×
“For example, some studies have fused GLP-1 molecules with Human serum albumin (Gao et al. 2009), or PEG-modified GLP-1, to increase its molecular volume(Li et al. 2020), while others have increased the half-life of GLP-1RAs by dimerization and antibody fusion(Scheen 2017).”
BackgroundBech, E. M., Martos-Maldonado, M. C., Wismann, P., Sørensen, K. K., van Witteloostuijn, S. B., Thygesen, M. B., Vrang, N., Jelsing, J., Pedersen, S. L., & Jensen, K. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00787 · Cited by 39 · cited 1×
“The AUC of the blood curve was reduced by approximately 60% compared with that of the vehicle(Bech et al. 2017).”
ResultTraitement médicamenteux du diabète de type 2 (première partie)
Tielmans, A., Laloi-Michelin, M., Coupaye, M., Virally, M., Meas, T., & Guillausseau, P.-J. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2006.10.017 · Cited by 35
Affinity Measurements by Competition ELISA
Martineau, P. (2010) · Springer eBooks · doi:10.1007/978-3-642-01144-3_41 · Cited by 25 · cited 2×
“After the reaction, the dissociation constant (Kd) between the target protein and GLP-1 receptor was calculated by plotting(Friguet et al. 1985; Bobrovnik 2003; Martineau 2010) (Kd is equal to the ligand concentration when half of the receptors are bound by ligands.”
BackgroundMethodKontermann, R., & DUBEL, S. J. (2010) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-3-642-01144-3 · Cited by 24
Perioperative fluid management: Progress despite lingering controversies
Hamilton, M. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s4.05 · Cited by 17
Ali, A. M., Mari, A., MARTINEZ, R. A., Jobori, H. A., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., Cersósimo, E., & Abdul‐Ghani, M. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa494 · Cited by 16 · cited 1×
“Additionally, GLP-1 has been shown to reduce Ca2+ influx, inhibiting the exocytosis of α cells, thereby inhibiting the release of glucagon [7].”
BackgroundA novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect
Li, C., Huan, Y., Shen, N., Ji, L., Sun, S., Liu, S., Liu, Q., Gao, L., Tan, F., Wang, Y., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.103 · Cited by 11 · cited 1×
“Interestingly, it was found that these mutations could severely weaken the binding ability of GLP-1 and its receptor, thus affecting the function of GLP-1(Adelhorst et al. 1994; Gallwitz et al. 2000; Green et al. 2004; Li et al. 2010).”
BackgroundMolek, P., Vodnik, M., Štrukelj, B., & Bratkovič, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.087 · Cited by 8 · cited 2×
“∞ [25], where A0 is the absorbance of the blank control at 450 nm, with an”
BackgroundLi, P., Zhang, J., Jia, Y., & Zhang, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117752 · Cited by 8 · cited 4×
“Furthermore, the same receptor affinity as wild-type GLP-1 can be maintained only when the molecular weight of PEG is less than 5 kDa; when the molecular weight of the PEG chain is expanded to 10 kDa or higher, the affinity between GLP-1RAs and the receptor will be significantly affected [32].”
BackgroundInfluentialNext-Generation GLP-1 Therapy: An Introduction to Liraglutide
Repas, T. B. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2480 · Cited by 4 · cited 1×
“Liraglutide and semaglutide have been chemically modified to connect the fatty chain to natural GLP-1 molecules and rely on the fatty chain to bind to albumin in the blood [18].”
BackgroundPratley, R. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa666 · Cited by 3
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“47, 48 By emulating the biological activity of natural GLP-1, GLP-1RAs effectively ful fi ll the role of GLP-1, effectively lowering blood glucose levels without increasing the risk of hypoglycemia and demonstrating favorable safety pro fi les.”
BackgroundSelf-citationRole of oxidative stress in the relationship between periodontitis and systemic diseases
Shang, J., Liu, H., Zheng, Y., & Zhang, Z. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1210449 · Cited by 155
Self-citationAdvances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
“GLP-1, an originally identified natu-ral prototype, is synthesized and secreted by intestinal enteroendocrine L-cells and certain neurons within The Journal of Headache and Pain replicating the pharmacological functions [6, 7].”
Self-citationObesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20
Barać, M., & Roganović, J. (2025) · Biology · doi:10.3390/biology14121650 · Cited by 32
Metadata
- Authors
- Sun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P.
- Affiliations
- University of Science and Technology of China (CN)
- Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei 230031, China
- MOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, National Science Center for Physical Sciences at Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230022, China
- Chinese Academy of Sciences (CN)
- Corresponding author
- Wang, Peng
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-06-13
- Volume
- 15
- Issue
- 6
- Pages
- 740
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9230455
- OpenAlex
- W4282831524
- Cited by
- 17
- References
- 53
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 2 · 2023: 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Major Projects of Science and Technology of Anhui Province (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
- China National Key Research and Development Program (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
- Development Plan of Anhui Province (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
- National Natural Science Foundation of China (202103a06020003, 2019YFA0904300, 2019YFA0904304, 1804b06020342, 91953101)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- GLP-1 receptor agonists, glucagon-like peptide-1, dipeptidyl peptidase IV, type 2 diabetes, antidiabetic drugs, drug stability, fusion protein, conformational change, ligand-receptor interactions, long-acting drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.